Tuesday, September 08, 2015 12:26:36 PM
Fact: 1 - Managment says once all warrants are exercised, total shares will be 199,783,272.
Fact: 2 - 59 million of those shares were purchased by "Investors" at 62 cents/share march 2015
Fact: 3 - 16 million net shares were purchased by banks between 50 and 75 cents in Q1 2015.
Fact: 4 - Included in the 199m total shares are assumed all warrants to be exercised.
Fact: 5 - All warrants outstanding (A - 81 cent ex price, B - 81 cent ex price, C - 62 cent ex price)
Fact: 6 - All previous warrants issued were paid off and closed as part of deal (no further dilution)
Fact: 7 - AEZS has Phase 3 Treatment for Cancer undergoing testing, might change cancer treatment.
Fact: 8 - AEZS has Phase 3 AGHD Detection Treatment undergoing testing, might change AGHD treatment.
Fact: 9 - July 28, 2015 announced licensing of tumor vaccine (AEZS-120) to German Life Sciences.
Fact:10 - July 27, 2014 announced Starting of Co-Promotion of Saizen with Merck in 25 US Territories.
Fact:11 - AEZS just release 2 back to back Licensing Agreements on July 27 and 28, aka NEW REVENUES.
Fact:12 - Susquehanna Int. Group purchased 8,538,953 shares AEZS between 50-75 cents in Q1 2015.
Fact:13 - Tenor Capital Managment purchased 5,732,967 shares AEZS between 50-75 cents in Q1 2015.
Fact:14 - DeerField Management Co purchased 898,574 shares of AEZS between 50-75 cents in Q1 2015.
Fact:15 - Renaissance Technologies purchased 563,700 shares of AEZS between 50-75 cents in Q1 2015.
Fact:16 - Millennium Management purchased 147,045 shares of AEZS between 50-75 cents in Q1 2015.
Fact:17 - Nine Chapters Capital added 95,100 to 369,600 position between 50-75 cents in Q1 2015.
Fact:18 - Creative Planning purchased 100,000 shares of AEZS between 27-66 cents in Q2 2015.
Fact:19 - AEZS had 53 million dollar Cash in Q1 2015 and Zero (that's 0.00) Debt
Fact:20 - The 59 million shares purchased at 62 cents could have been loaned to shortsellers.
Fact:21 - The Bazillions of Bashers parading around may be helping short sellers Cover this position.
Fact:22 - The Cashless Warrant Provision of the A and B warrants went into effect May 27, 2015.
Fact:23 - The Execution of Cashless Warrants allows % of Warrants to be sold into market to exercise rest.
Fact:24 - You can think of this cashless warrants as selling 2 share into market to keep other 8 shares.
Fact:25 - Exercising of Cashless warrants is easy way to accumulate huge positions without chasing stock.
Fact:26 - These Warrant holders are essentially able to accumulate large positions in AEZS this way.
Fact:27 - Shortsellers knowing this supply of shares will be available, can short high, and cover low.
Fact:28 - As Warrants are exercised, exercise warrant shares sold, could be bought by short sellers to cover.
Fact:29 - Loaning out of shares to short sellers for interest is common in Wall Street and Legal.
Fact:30 - Once these warrants are fully exercised, all selling dries up in stock, shorts have to cover.
Fact:31 - AEZS owns a Patent Suite of over 80 families of Patents, each family with numerous patents.
Fact:32 - AEZS Managment has announced that they intend to leverage this suite of products in license deals.
Fact:33 - AEZS Managment has hinted that revenues from marketing partnerships will ramp up in Q2.
Fact:34 - AEZS will provide details of new revenues from 2 new licensing details on Q2 conference call.
Fact:35 - I have accumulated a large Position in AEZS with an average share price of 24 cents.
Fact:36 - I expect that once warrant conversion finished and large short positions cover, AEZS will rocket.
Fact:37 - I expect 150m of 199m float will be owned by investors via bank accumulation and warrant exercise soon.
Fact:38 - I believe that Insiders are not buying currently due to a company insider blackout that will end soon.
Fact:40 - This AEZS stock is a TREMENDOUS buying opportunity, and will become an explosive stock in 2015 - 2016.
Recent AEZS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 12:00:34 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/17/2024 12:00:32 PM
- Aeterna Zentaris Announces Details Regarding Transaction with Ceapro • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:13 AM
- Aeterna Zentaris Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 10:00:00 PM
- Aeterna Zentaris Announces Effective Date of Share Consolidation • GlobeNewswire Inc. • 05/01/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 03/27/2024 12:05:00 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:53 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro • GlobeNewswire Inc. • 02/15/2024 10:50:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/15/2024 09:54:45 PM
- Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:33:18 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:42:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 12:50:09 PM
- Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 12/14/2023 12:50:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:15 PM
- Aeterna Zentaris Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM